Engineered variants of human glutamic acid decarboxylase (GAD) and autoantibody epitope recognition

Clinical Immunology

Volumn 108, Issue 1, 2003, Pages 38-45

  Primo, M E ^a   Anton, E A ^b   Villanueva, A L ^a   Poskus, E ^a,c   Ermacora M R ^b,c  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^b UNIVERSIDAD NACIONAL DE QUILMES   (Argentina)

^c Facultad de Ciencias Naturales e Instituto M Lillo   (Argentina)

Author keywords

Autoantibodies; Autoimmune thyroid disease; Autoimmunity; Diabetes; Epitopes; Glutamic acid decarboxylase; Radioimmunoassay; Recombinant protein

Indexed keywords

AUTOANTIBODY; ENZYME VARIANT; EPITOPE; GLUTAMATE DECARBOXYLASE; HYBRID PROTEIN;

ADOLESCENT; ADULT; AGED; AMINO TERMINAL SEQUENCE; ARTICLE; AUTOIMMUNITY; CARBOXY TERMINAL SEQUENCE; CHILD; CONTROLLED STUDY; CROSS REACTION; DNA PROBE; FEMALE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; MATURITY ONSET DIABETES MELLITUS; MOLECULAR RECOGNITION; PRIORITY JOURNAL; PROTEIN ENGINEERING; RADIOIMMUNOASSAY; SCHOOL CHILD; SEQUENCE HOMOLOGY; THYROID DISEASE;

EID: 0038351786     PISSN: 15216616     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1521-6616(03)00061-5     Document Type: Article

References (35)

1. Bu D.F., Erlander M.G., Hitz B.C., Tillakaratne N.J., Kaufman D.L., Wagner-McPherson C.B., Evans G.A., Tobin A.J. Two human glutamate decarboxylases, 65-kDa GAD and 67-kDa GAD, are each encoded by a single gene. Proc. Natl. Acad. Sci. USA. 89:1992;2115-2119.
2. Dirkx R.J., Thomas A., Li L., Lernmark A., Sherwin R.S., De Camilli P., Solimena M. Targeting of the 67-kDa isoform of glutamic acid decarboxylase to intracellular organelles is mediated by its interaction with the NH2-terminal region of the 65-kDa isoform of glutamic acid decarboxylase. J. Biol. Chem. 270:1995;2241-2246.
3. Solimena M., Folli F., Denis-Donini S., Comi G.C., Pozza G., De Camilli P., Vicari A.M. Autoantibodies to glutamic acid decarboxylase in a patient with stiff-man syndrome, epilepsy, and type 1 diabetes mellitus. N. Engl. J. Med. 318:1999;1012-1020.
4. Baekkeskov S., Aanstoot H.J., Christgau S., Reetz A., Solimena M., Cascalho M., Folli F., Richter-Olesen H., DeCamilli P., Camilli P.D. Identification of the 64K autoantigen in insulin-dependent diabetes as the GABA-synthesizing enzyme glutamic acid decarboxylase. Nature. 347:1990;151-156.
5. Björk E., Velloso L.A., Kämpe O., Karlsson F.A. GAD autoantibodies in IDDM, stiff-man syndrome, and autoimmune polyendocrine syndrome type I recognize different epitopes. Diabetes. 43:1994;161-165.
6. Maugendre D., Vérité F., Guilhem I., Genetet B., Allannic H., Delamaire M. Anti-pancreatic autoimmunity and Graves' disease study of a cohort of 600 Caucasian patients . Eur. J. Endocrinol. 137:1997;503-510.
7. De Aizpurua H.J., Wilson Y.M., Harrison L.C. Glutamic acid decarboxylase autoantibodies in preclinical insulin-dependent diabetes. Proc. Natl. Acad. Sci. USA. 89:1992;9841-9845.
8. Hagopian W.A., Karlsen A.E., Gottsäter A., Landin-Olsson M., Grubin C.E., Sundkvist G., Petersen J.S., Boel E., Dyrberg T., Lernmark A. Quantitative assay using recombinant human islet glutamic acid decarboxylase (GAD65) shows that 64K autoantibody positivity at onset predicts diabetes type. J. Clin. Invest. 91:1993;368-374.
9. Rowley M.J., Mackay I.R., Chen Q.Y., Knowles W.J., Zimmet P.Z. Antibodies to glutamic acid decarboxylase discriminate major types of diabetes mellitus. Diabetes. 41:1992;548-551.
10. Bingley P.J., Bonifacio E., Williams A.J., Genovese S., Bottazzo G.F., Gale E.A. Prediction of IDDM in the general population strategies based on combinations of autoantibody markers . Diabetes. 46:1997;1701-1710.
11. Richter W., Shi Y., Baekkeskov S. Autoreactive epitopes defined by diabetes-associated human monoclonal antibodies are localized in the middle and C-terminal domains of the smaller form of glutamate decarboxylase. Proc. Natl. Acad. Sci. USA. 90:1993;2832-2836.
12. Tuomi T., Rowley M.J., Knowles W.J., Chen Q.Y., McAnally T., Zimmet P.Z., Mackay I.R. Autoantigenic properties of native and denatured glutamic acid decarboxylase evidence for a conformational epitope . Clin. Immunol. Immunopathol. 71:1994;53-59.
13. Daw K., Powers A.C. Two distinct glutamic acid decarboxylase auto-antibody specificities in IDDM target different epitopes. Diabetes. 44:1995;216-220.
14. Papouchado M.L., Ermácora M.R., Poskus E. Detection of glutamic acid decarboxylase (GAD) autoantibodies by indirect immunofluorescence using CHO cells expressing recombinant human GAD65. J. Autoimmun. 9:1996;689-697.
15. Syren K., Lindsay L., Stoehrer B., Jury K., Lühder F., Baekkeskov S., Richter W. Immune reactivity of diabetes-associated human monoclonal autoantibodies defines multiple epitopes and detects two domain boundaries in glutamate decarboxylase. J. Immunol. 157:1996;5208-5214.
16. Sohnlein P., Muller M., Syren K., Hartmann U., Bohm B.O., Meinck H.M., Knip M., Akerblom H.K., Richter W. Epitope spreading and a varying but not disease-specific GAD65 antibody response in Type 1 diabetes. The Childhood Diabetes in Finland Study Group. Diabetologia. 43:2000;210-217.
17. Daw K., Ujihara N., Atkinson M., Powers A.C. Glutamic acid decarboxylase autoantibodies in stiff-man syndrome and insulin-dependent diabetes mellitus exhibit similarities and differences in epitope recognition. J. Immunol. 156:1996;818-825.
18. Powers A.C., Bavik K., Tremble J., Daw K., Scherbaum W.A., Banga J.P. Comparative analysis of epitope recognition of glutamic acid decarboxylase (GAD) by autoantibodies from different autoimmune disorders. Clin. Exp. Immunol. 118:1999;349-356.
19. Falorni A., Ackefors M., Carlberg C., Daniels T., Persson B., Robertson J., Lernmark A. Diagnostic sensitivity of immunodominant epitopes of glutamic acid decarboxylase (GAD65) autoantibodies in childhood IDDM. Diabetologia. 39:1996;1091-1098.
20. Teoh K.L., Fida S., Rowley M.J., Mackay I.R. Autoantigenic reactivity of diabetes sera with a hybrid glutamic acid decarboxylase GAD67-65 molecule GAD67 (1-101)/GAD65(96-585). Autoimmunity. 28:1998;259-266.
21. Falorni A., Gambelunghe G., Forini F., Kassi G., Cosentino A., Candeloro P., Bolli G.B., Brunetti P., Calcinaro F. Autoantibody recognition of COOH-terminal epitopes of GAD65 marks the risk for insulin requirement in adult-onset diabetes mellitus. J. Clin. Endocrinol. Metab. 85:2000;309-316.
22. Bonifacio E., Lampasona V., Bernasconi L., Ziegler A.G. Maturation of the humoral autoimmune response to epitopes of GAD in preclinical childhood type 1 diabetes. Diabetes. 49:2000;202-208.
23. Hampe C.S., Ortqvist E., Rolandsson O., Landin-Olsson M., Törn C., Agren A., Persson B., Schranz D.B., Lernmark A. Species-specific autoantibodies in type 1 diabetes. J. Clin. Endocrinol. Metab. 84:1999;643-648.
24. Walpole R.E., Myers R.H. Probability and Statistics for Engineers and Scientists. 1993;Prentice-Hall, London.
25. Santos J., Anton E.A., Buslje C.M., Valdez S.N., Villanueva A.L., Sica M., Iacono R., Maffia P., Poskus E., Ermacora M.R. Replacement of methionine-161 with threonine eliminates a major by-product of human glutamate decarboxylase 65-kDa variant expression i. Escherichia coli, Biotechnol. Appl. Biochem. 31:(Pt. 3):2000;205-212.
26. Papouchado M.L., Valdez S.N., Ghiringhelli D., Poskus E., Ermácora M.R. Expression of properly folded human glutamate decarboxylase 65 as a fusion protein in Escherichia coli. Eur. J. Biochem. 246:1997;350-359.
27. Diabetes Mellitus: Report of a WHO Study Group, Tech. Rep. Ser. 727, World Health Organization, Geneva, 1985.
28. Grubin C.E., Daniels T., Toivola B., Landin-Olsson M., Hagopian W.A., Li L., Karlsen A.E., Boel E., Michelsen B., Lernmark A. A novel radioligand binding assay to determine diagnostic accuracy of isoform-specific glutamic acid decarboxylase antibodies in childhood IDDM. Diabetologia. 37:1994;344-350.
29. Powell M., Prentice L., Asawa T., Kato R., Sawicka J., Tanaka H., Petersen V., Munkley A., Morgan S., Rees Smith B., Furmaniak J. Glutamic acid decarboxylase autoantibody assay using 1251-labelled recombinant GAD65 produced in yeast. Clin. Chim. Acta. 256:1996;175-188.
30. Shi Y., Veit B., Baekkeskov S. Amino acid residues 24-31 but not palmitoylation of cysteines 30 and 45 are required for membrane anchoring of glutamic acid decarboxylase, GAD65. J. Cell. Biol. 124:1994;927-934.
31. Hagopian W.A., Michelsen B., Karlsen A.E., Larsen F., Moody A., Grubin C.E., Rowe R., Petersen J., McEvoy R., Lernmark A. Autoantibodies in IDDM primarily recognize the 65,000-M(r) rather than the 67,000-M(r) isoform of glutamic acid decarboxylase. Diabetes. 42:1993;631-636.
32. Ujihara N., Daw K., Gianani R., Boel E., Yu L., Powers A.C. Identification of glutamic acid decarboxylase autoantibody heterogeneity and epitope regions in type 1 diabetes. Diabetes. 43:1994;968-975.
33. Vandewalle C.L., Falorni A., Svanholm S., Lernmark A., Pipeleers D.G., Gorus F.K. High diagnostic sensitivity of glutamate decarboxylase autoantibodies in insulin-dependent diabetes mellitus with clinical onset between age 20 and 40 years. The Belgian Diabetes Registry. J. Clin. Endocrinol. Metab. 80:1995;846-851.
34. Zimmet P., Turner R., McCarty D., Rowley M., Mackay I. Crucial points at diagnosis. Type 2 diabetes or slow type 1 diabetes. Diabetes Care. 22:(Suppl 2):1999;B59-64.
35. Hallengren B., Falorni A., Landin-Olsson M., Lernmark A., Papadopoulos K.I., Sundkvist G. Islet cell and glutamic acid decarboxylase antibodies in hyperthyroid patients at diagnosis and following treatment . J. Intern. Med. 239:1996;63-68.